Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
121.9 ^USD	+0.68%		+9.36%	+22.56%

May. 07	UBS Adjusts Moderna Price Target to $151 From $143, Maintains Buy Rating	MT
May. 06	News Highlights : Top Financial Services News of the Day - Monday at 4 PM ET	DJ

Pfizer, BioNTech countersue Moderna over COVID-19 vaccine patents

December 05, 2022 at 06:13 pm EST

(Reuters) - Pfizer Inc and its German partner BioNTech SE fired back on Monday at a patent lawsuit filed by Moderna Inc in Boston federal court over their rival COVID-19 vaccines, seeking a dismissal of the lawsuit and a court order that they did not infringe Moderna's patents.

(Reporting by New York Newsroom; Editing by Mark Porter)

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
MODERNA, INC.	121.9 USD	+0.68%	+9.36%	46.71B
BIONTECH SE	90.13 USD	-0.83%	+0.20%	21.72B
PFIZER, INC.	28.27 USD	+1.80%	+4.01%	160B

Latest news about Moderna, Inc.

UBS Adjusts Moderna Price Target to $151 From $143, Maintains Buy Rating	May. 07	MT
News Highlights : Top Financial Services News of the Day - Monday at 4 PM ET	May. 06	DJ
News Highlights : Top Financial Services News of the Day - Monday at 11 AM ET	May. 06	DJ
News Highlights : Top Financial Services News of the Day - Monday at 7 AM ET	May. 06	DJ
North American Morning Briefing : Stock Futures Rise as Hopes of Rate Cut Return	May. 06	DJ
News Highlights : Top Global Markets News of the Day - Monday at 5 AM ET	May. 06	DJ
Moderna Insider Sold Shares Worth $1,663,855, According to a Recent SEC Filing	May. 06	MT
News Highlights : Top Global Markets News of the Day - Monday at 3 AM ET	May. 06	DJ
News Highlights : Top Global Markets News of the Day - Monday at 1 AM ET	May. 06	DJ
News Highlights : Top Financial Services News of the Day - Monday at 12 AM ET	May. 06	DJ
News Highlights : Top Global Markets News of the Day - Sunday at 11 PM ET	May. 05	DJ
News Highlights : Top Global Markets News of the Day - Sunday at 9 PM ET	May. 05	DJ
Jefferies Adjusts Price Target on Moderna to $155 From $125	May. 03	MT
Oppenheimer Adjusts Price Target on Moderna to $163 From $142	May. 03	MT
Goldman Sachs Adjusts Price Target on Moderna to $204 From $206	May. 03	MT
Leerink Adjusts Price Target on Moderna to $60 From $59	May. 03	MT
Morgan Stanley Adjusts Price Target on Moderna to $95 From $89	May. 03	MT
Jefferies & Co Adjusts Moderna Price Target to $155 From $125	May. 03	MT
Goldman Sachs Adjusts Moderna Price Target to $204 From $206	May. 03	MT
Morgan Stanley Raises Price Target on Moderna to $95 From $89, Keeps Equalweight Rating	May. 03	MT
RBC Raises Price Target on Moderna to $135 From $125 on 'More Prudent Financial Outlook,' Keeps Outperform Rating	May. 03	MT
ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna...	May. 03
MODERNA : price target raised by Oddo BHF	May. 03	CF
Wall Street: optimism ahead of NFP, rates ease	May. 03	CF
Wall Street: optimism ahead of NFP, rates ease	May. 02	CF

Chart Moderna, Inc.

Duration

Period

More charts

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - RBC Capital Markets Global Healthcare Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Moderna, Inc. prepares for the post-Covid era

March 25, 2024 at 10:24 am EDT

Stéphane Bancel, CEO of Moderna: Restoring confidence in the vaccines sector

January 16, 2024 at 03:31 pm EST

More Strategies

Ratings for Moderna, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

121.9 USD

Average target price

138.7 USD

Spread / Average Target

+13.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+22.56%	46.71B
IQVIA HOLDINGS INC.	-1.51%	41.52B
LONZA GROUP AG	+48.83%	41.8B
CELLTRION, INC.	-3.42%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.13%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.44%	19.26B
MEDPACE HOLDINGS, INC.	+26.45%	11.98B
BIO-TECHNE CORPORATION	-0.14%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.47%	12.08B
UNITED THERAPEUTICS CORPORATION	+18.74%	11.58B

Other Biotechnology & Medical Research